Pricing

Five things for pharma marketers to know: Tuesday March 3

Five things for pharma marketers to know: Tuesday March 3

By

NICE greenlights Harvoni for Britain's national formulary, Pacira received a CRL instead of an expanded indication and Novo's latest diabetes outreach focuses on patients instead of drug brands.

Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence

Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence

By

Drugmakers face increasing pressure on pricing from insurers and PBMs.

UK doctors lobby for off-label Avastin use

Doctors want the National Health Service to allow them to prescribe the oncology drug for wet age-related macular degeneration.

California ponders drug pricing reveal

Assemblyman David Chiu's bill would publish a drug's R&D and related costs.

Study shows Lucentis at Eylea disadvantage

Study shows Lucentis at Eylea disadvantage

By

An NIH study shows possible limit to Lucentis's appeal.

Specialty medications have PBMs on edge

Specialty medications have PBMs on edge

By

CVS health execs write that cost of long-term specialty medications, not short-timers like Sovaldi, are a major worry.

CDC: diabetes patient costs have doubled

The reason: higher prices and more services.

Ireland takes hard line on Rx prices

The health minister is threatening price-related legislation.

2013 healthcare spending crept upwards

2013 healthcare spending crept upwards

By

Centers for Medicare and Medicaid Services says it is too early to blame a sluggish economy for slow growth.

Gilead may be forced to discount hep. C pills

AbbVie's deal with the PBM Express Scripts has altered the dynamic in hepatitis C price-setting, writes Bloomberg.

High deductibles, costs keep patients away

High deductibles, costs keep patients away

By

More cost data for the file the latest data shows that up-front healthcare costs are prompting many patients to delay office visits.

World projected to spend $1T on drugs in 2018

World projected to spend $1T on drugs in 2018

By

The IMS Institute for Healthcare Informatics notes that developed markets remain a key driver.

Cigna lowers price of some HIV medications

The deal will cap the monthly price some patients may pay for medications such as Atripla.

Specialty prescription costs hurt across the board

Specialty prescription costs hurt across the board

By

Solutions for how to handle specialty medication costs are lacking, but the data around them shows a need for serious problem-solving.

Nearly half of consumers wary of healthcare costs, insurer finds

Nearly half of consumers wary of healthcare costs, insurer finds

By

Cigna said found paying for medications and hospitalizations were top healthcare concerns.

Five things for pharma marketers to know: Friday, September 19

Five things for pharma marketers to know: Friday, September 19

By

Lilly's weekly GLP-1 shot is approved, BI expands its lung-cancer portfolio, GSK's China investigation closes, NY proposed Sovaldi triage and India imposed price limits on 36 new medicines.

DOJ eyes Ranbaxy pricing

The Department of Justice is looking into Medicaid pricing.

Switzerland wants lower drug prices

Switzerland is pushing Roche to lower its prices on Perjeta

Drug spend will continue to rise through 2023

Drug spend will continue to rise through 2023

By

The numbers folks at the Centers for Medicare and Medicaid Services anticipate sluggish growth in US healthcare spend, but prescriptions look ready to take off.

Study: move more, eat less, save $500

Diet and exercise can help some type-2 diabetes patients save around $500 in medical expenses every year.

 Five things for pharma marketers to know: Friday, August 15

Five things for pharma marketers to know: Friday, August 15

By

UK drug-cost watchdog backs Sovaldi, Achillion touts HCV interim results, Avastin's latest cancer indication, Ebola outbreak worsens, COPD drug gets panel nod, and study links quick reviews and black-box warnings.

Britain's NICE sidelines Kadcyla

Britain's NICE sidelines Kadcyla

By

Britain's National Institute for Health and Care Excellence has followed through on its Kadcyla objections and has said Roche's breast cancer drug will remain off the National Health Services formulary because it is too expensive.

Site has doctors bid for business

Medibid users auction up care in exchange for a low price.

WellPoint tests prices, patients

Health insurer WellPoint found patients chose lower-priced MRIs when shown how much locations charged for the very same procedure, but the motivation is murky.

Acthar marketing drives prescriptions and anger

The decades-old drug is winning prescriptions through marketing, but has a free-pass when it comes to clinical trial data.

Express Scripts drops Zohydro, brings back Advair

The PBM dropped 25 more drugs from its formulary.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on horizon

By

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Generics trigger wallet shock

Prices for some generics are rising, thanks to limited competition.

Experiment cuts cancer costs, ups drug spend

UnitedHealthcare finds drug costs more than doubled.

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters